{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T13:58:05Z","timestamp":1721311085053},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring <jats:italic>epidermal growth factor receptor (EGFR)<\/jats:italic> mutations. Although malignant pleural effusion (PE) is a common clinical problem in NSCLC, information about the efficacy of osimertinib in patients with PE is limited, especially regarding its efficacy in <jats:italic>EGFR<\/jats:italic> T790M-negative patients with PE remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed the medical records of patients with NSCLC harboring <jats:italic>EGFR<\/jats:italic> mutations who were treated with osimertinib in our institution between May 2016 and December 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 63 patients with <jats:italic>EGFR<\/jats:italic> mutated NSCLC were treated with osimertinib; 33 (12 with PE) had no <jats:italic>EGFR<\/jats:italic> T790M mutation, while 30 (12 with PE) had <jats:italic>EGFR<\/jats:italic> T790M mutation. In <jats:italic>EGFR<\/jats:italic> T790M-negative NSCLC, the progression-free survival (PFS) of the patients with PE was comparable to that of the patients without PE (median PFS 19.8 vs. 19.8\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.693). In <jats:italic>EGFR<\/jats:italic> T790M- positive NSCLC, the PFS and overall survival (OS) of the patients with PE were significantly shorter than those of the patients without PE (median PFS 16.8 vs. 8.3\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.003; median OS 44.9 vs. 14.2\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.007). In the multivariate analysis, the presence of PE was independently associated with shorter PFS and OS in <jats:italic>EGFR<\/jats:italic> T790M-positive NSCLC patients, but not <jats:italic>EGFR<\/jats:italic> T790M-negative patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data suggest the efficacy of osimertinib may differ between <jats:italic>EGFR<\/jats:italic> T790M-positive and -negative NSCLC patients with PE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09701-2","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:02:52Z","timestamp":1654066972000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion"],"prefix":"10.1186","volume":"22","author":[{"given":"Hiroshi","family":"Nokihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohiko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Yabuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"9701_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","volume":"7","author":"D Morgensztern","year":"2012","unstructured":"Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7:1485\u20139. https:\/\/doi.org\/10.1097\/JTO.0b013e318267223a.","journal-title":"J Thorac Oncol"},{"key":"9701_CR2","first-page":"47","volume":"3","author":"S Sugiura","year":"1997","unstructured":"Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res. 1997;3:47\u201350.","journal-title":"Clin Cancer Res"},{"key":"9701_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1200\/JCO.2013.50.5453","volume":"32","author":"JS Ryu","year":"2014","unstructured":"Ryu JS, Ryu HJ, Lee SN, Memon A, Lee SK, Nam HS, Kim HJ, Lee KH, Cho JH, Hwang SS. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol. 2014;32:960\u20137. https:\/\/doi.org\/10.1200\/JCO.2013.50.5453.","journal-title":"J Clin Oncol"},{"key":"9701_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1177\/0300060514539273","volume":"42","author":"J Zou","year":"2014","unstructured":"Zou J, Bella AE, Chen Z, Han X, Su C, Lei Y, Luo H. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation. J Int Med Res. 2014;42:1110\u20137. https:\/\/doi.org\/10.1177\/0300060514539273.","journal-title":"J Int Med Res"},{"key":"9701_CR5","doi-asserted-by":"publisher","first-page":"13574","DOI":"10.1038\/srep13574","volume":"5","author":"MF Tsai","year":"2015","unstructured":"Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC, Yang PC, Shih JY. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci Rep. 2015;5:13574. https:\/\/doi.org\/10.1038\/srep13574.","journal-title":"Sci Rep"},{"key":"9701_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.2217\/fon-2016-0163","volume":"12","author":"S Atagi","year":"2016","unstructured":"Atagi S, Goto K, Seto T, Yamamoto N, Tamura T, Tajima K, Inagaki N. Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies. Future Oncol. 2016;12:2117\u201326. https:\/\/doi.org\/10.2217\/fon-2016-0163.","journal-title":"Future Oncol"},{"key":"9701_CR7","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.3892\/ol.2017.7125","volume":"14","author":"Y Taniguchi","year":"2017","unstructured":"Taniguchi Y, Tamiya A, Nakahama K, Naoki Y, Kanazu M, Omachi N, Okishio K, Kasai T, Atagi S. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first- generation EGFR-tyrosine kinase inhibitors. Oncol Lett. 2017;14:7589\u201396. https:\/\/doi.org\/10.3892\/ol.2017.7125.","journal-title":"Oncol Lett"},{"key":"9701_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376:629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"key":"9701_CR9","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","volume":"31","author":"VA Papadimitrakopoulou","year":"2020","unstructured":"Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31:1536\u201344. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2100.","journal-title":"Ann Oncol"},{"key":"9701_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med."},{"key":"9701_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC, FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med."},{"key":"9701_CR12","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.21873\/anticanres.12629","volume":"38","author":"K Masuhiro","year":"2018","unstructured":"Masuhiro K, Shiroyama T, Suzuki H, Takata SO, Nasu S, Takada H, Morita S, Tanaka A, Morishita N, Okamoto N, Hirashima T. Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M. Anticancer Res. 2018;38:3567\u201371. https:\/\/doi.org\/10.21873\/anticanres.12629.","journal-title":"Anticancer Res."},{"key":"9701_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10637-019-00808-1","volume":"38","author":"T Kawamura","year":"2020","unstructured":"Kawamura T, Kenmotsu H, Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Endo M, Takahashi T. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. Invest New Drugs. 2020;38:194\u2013201. https:\/\/doi.org\/10.1007\/s10637-019-00808-1.","journal-title":"Invest New Drugs."},{"key":"9701_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/jjco\/hyaa067","volume":"50","author":"Y Ohe","year":"2020","unstructured":"Ohe Y, Kato T, Sakai F, Kusumoto M, Endo M, Saito Y, Baba T, Sata M, Yamaguchi O, Sakamoto K, Sugeno M, Tamura R, Tokimoto T, Shimizu W, Gemma A. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. Jpn J Clin Oncol. 2020;50:909\u201319. https:\/\/doi.org\/10.1093\/jjco\/hyaa067.","journal-title":"Jpn J Clin Oncol"},{"key":"9701_CR15","doi-asserted-by":"publisher","first-page":"e8951","DOI":"10.1371\/journal.pone.0089518","volume":"e8951","author":"S Benlloch","year":"2014","unstructured":"Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capit\u00e1n A, de\u00a0Aguirre I, Queralt C, Ramirez JL, Ram\u00f3n y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, Taron M. Clinical\nvalidation of a PCR assay for the detection of EGFR mutations in non-small-cell\nlung cancer: retrospective testing of specimens from the EURTAC trial. PLoS One. 2014;e8951:e8951. https:\/\/doi.org\/10.1371\/journal.pone.0089518.","journal-title":"PLoS One"},{"key":"9701_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford D, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"9701_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"9701_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11912-013-0315-7","volume":"15","author":"M Bradshaw","year":"2013","unstructured":"Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15:207\u201316. https:\/\/doi.org\/10.1007\/s11912-013-0315-7.","journal-title":"Curr Oncol Rep"},{"key":"9701_CR19","doi-asserted-by":"publisher","first-page":"e12978","DOI":"10.14814\/phy2.12978","volume":"4","author":"E Fafliora","year":"2016","unstructured":"Fafliora E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG. Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiol Rep. 2016;4:e12978. https:\/\/doi.org\/10.14814\/phy2.12978.","journal-title":"Physiol Rep"},{"key":"9701_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/cas.14801","volume":"112","author":"H Watanabe","year":"2021","unstructured":"Watanabe H, Ichihara E, Kayatani H, Makimoto G, Ninomiya K, Nishii K, Higo H, Ando C, Okawa S, Nakasuka T, Kano H, Hara N, Hirabae A, Kato Y, Ninomiya T, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. Cancer Sci. 2021;112:1853\u201364. https:\/\/doi.org\/10.1111\/cas.14801.","journal-title":"Cancer Sci"},{"key":"9701_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1091\/mbc.4.1.121","volume":"4","author":"CK Goldman","year":"1993","unstructured":"Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4:121\u201333. https:\/\/doi.org\/10.1091\/mbc.4.1.121.","journal-title":"Mol Biol Cell"},{"key":"9701_CR22","first-page":"5090","volume":"61","author":"A Viloria-Petit","year":"2001","unstructured":"Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001;61:5090\u2013101.","journal-title":"Cancer Res"},{"key":"9701_CR23","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, J\u00e4nne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15:3484\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2904.","journal-title":"Clin Cancer Res"},{"key":"9701_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(14)70381-X.","journal-title":"Lancet Oncol"},{"key":"9701_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X.","journal-title":"Lancet Oncol"},{"issue":"1655","key":"9701_CR26","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(1655):1669. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5.","journal-title":"Lancet Oncol."},{"issue":"Suppl 9","key":"9701_CR27","doi-asserted-by":"publisher","first-page":"ix125","DOI":"10.1093\/annonc\/mdv532.04","volume":"26","author":"Y Hosomi","year":"2015","unstructured":"Hosomi Y, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Tajima K, Inagaki N, Yamamoto M. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non\u2013small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis. Ann Oncol. 2015;26(Suppl 9):ix125\u201347.","journal-title":"Ann Oncol"},{"key":"9701_CR28","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1016\/j.cllc.2019.02.016","volume":"20","author":"O Hiranuma","year":"2019","unstructured":"Hiranuma O, Uchino J, Yamada T, Chihara Y, Tamiya N, Kaneko Y, Yoshimura K, Takayama K. Rationale and Design of a Phase II Trial of Osimertinib combined with bevacizumab in patients with untreated epidermal growth factor receptor-mutated non-small-cell lung cancer and malignant pleural and\/or pericardial effusion (SPIRAL II Study). Clin Lung Cancer. 2019;20:e402\u20136. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.016.","journal-title":"Clin Lung Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09701-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:05:25Z","timestamp":1654067125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09701-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9701"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09701-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"26 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethics Committee of Tokushima University. Because of its retrospective nature, the need for written informed consent was waived by the Ethics Committee of Tokushima University. All methods were carried out in accordance with Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hiroshi Nokihara has received research grant funding from AstraZeneca K.K, Chugai Pharmaceutical Co., Ltd., Nippon Pfizer Japan Inc., and speaker fees as honoraria from AstraZeneca K.K, Chugai Pharmaceutical Co., Nippon Boehringer lngelheim Co., Ltd., Eli Lilly Japan K.K., outside the submitted work. Yasuhiko Nishioka has received research grant funding from Chugai Pharmaceutical Co., Ltd., Nippon Boehringer lngelheim Co., Ltd., donation from Chugai Pharmaceutical Co., Ltd., Nippon Boehringer lngelheim Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., and speaker fees as honoraria from AstraZeneca K.K, Chugai Pharmaceutical Co., Ltd., Nippon Boehringer lngelheim Co., Ltd., Pfizer Japan Inc., Eli Lilly Japan K.K. outside the submitted work. The other authors have declared no conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"597"}}